Gene · 8741
Papers1,439
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 1,439
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Patients With Immunoglobulin A Nephropathy Show Abnormal Frequencies of B Cell Subsets, Unconventional T Cells, and High Levels of Galactose-Deficient IgA1-Coated Gut Bacteria. | Kidney Int Rep | 2025 | 39990906 | PubTator, text mining | PubMed |
| Cancer-secreted exosomal miR-1246 promotes colorectal cancer liver metastasis by activating hepatic stellate cells. | Mol Med | 2025 | 39979806 | PubTator, text mining | PubMed |
| Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy. | J Am Soc Nephrol | 2025 | 39462308 | PubTator, text mining | PubMed |
| The pathogenesis of IgA nephropathy and implications for treatment. | Nat Rev Nephrol | 2025 | 39232245 | PubTator, text mining | PubMed |
| 100% oxygen mobilizes stem cells and up-regulates MIF and APRIL in humans: a new point on the hormetic dose curve. | Front Cell Dev Biol | 2024 | 39974348 | PubTator, text mining | PubMed |
| What is new in the pathogenesis and treatment of IgA glomerulonephritis. | World J Nephrol | 2024 | 39723359 | PubTator, text mining | PubMed |
| The Latest Progress in the Application of Telitacicept in Autoimmune Diseases. | Drug Des Devel Ther | 2024 | 39664967 | PubTator, text mining | PubMed |
| The emerging role of BLyS/APRIL in autoimmune diseases: Biological characteristics, functions, and therapeutic potential. | J Autoimmun | 2024 | 39504927 | PubTator, text mining | PubMed |
| A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults. | Clin Transl Sci | 2024 | 39494621 | PubTator, text mining | PubMed |
| TNFSF13 insufficiency disrupts human colonic epithelial cell-mediated B cell differentiation. | bioRxiv | 2024 | 39386555 | PubTator, text mining | PubMed |
| State-of-Art Therapeutics in IgA Nephropathy. | Indian J Nephrol | 2024 | 39372635 | PubTator, text mining | PubMed |
| APRIL/BAFF upregulation is associated with clonal B-cell expansion in Hunner-type interstitial cystitis. | J Pathol | 2024 | 39360360 | PubTator, text mining | PubMed |
| B cell targeting in IgA nephropathy. | Nephrology (Carlton) | 2024 | 39327767 | PubTator, text mining | PubMed |
| Different estimation techniques and data analysis for constant-partially accelerated life tests for power half-logistic distribution. | Sci Rep | 2024 | 39242750 | PubTator, text mining | PubMed |
| Moderate Aerobic Exercise Induces Homeostatic IgA Generation in Senile Mice. | Int J Mol Sci | 2024 | 39125769 | PubTator, text mining | PubMed |
| Profiles of cytokines in patients with antineutrophil cytoplasmic antibody-associated vasculitis. | Front Immunol | 2024 | 39108259 | PubTator, text mining | PubMed |
| Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial. | J Immunother Cancer | 2024 | 38862251 | PubTator, text mining | PubMed |
| Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis. | Hum Genomics | 2024 | 38659056 | PubTator, text mining | PubMed |
| Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy. | Expert Opin Biol Ther | 2024 | 38641998 | PubTator, text mining | PubMed |
| M2 macrophage-derived paracrine factor TNFSF13 affects the fibrogenic alterations in endothelial cells and cardiac fibroblasts by mediating the NF-κB and Akt pathway. | J Biochem Mol Toxicol | 2024 | 38622979 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8741/papers?page=4